| Identification | Back Directory | [Name]
LORAZEPAM-D4 | [CAS]
84344-15-0 | [Synonyms]
LORAZEPAM-D4
Lorazepam-d4 solution
LORAZEPAM-D4,100/MLINACETONITRILE
LORAZEPAM (D4, 98%) 1.0 MG/ML IN ACETONITRILE
LORAZEPAM (D4, 98%) 100 UG/ML IN ACETONITRILE
2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(6-chlorophenyl-2,3,4,5-d4)-1,3-dihydro-3-hydroxy-
7-chloro-5-(2-chloro-3,4,5,6-tetradeuteriophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one | [EINECS(EC#)]
200-835-2 | [Molecular Formula]
C15H10Cl2N2O2 | [MDL Number]
MFCD00673284 | [MOL File]
84344-15-0.mol | [Molecular Weight]
321.16 |
| Hazard Information | Back Directory | [Uses]
Lorazepam-d4 is labelled Lorazepam (L469850) which is a high-potency, intermediate-duration, 3-hydroxy benzodiazepine drug, It is often used to treat anxiety disorders. | [References]
[1] L G MILLER. Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased gamma-aminobutyric acidA receptor function.[J]. Journal of Pharmacology and Experimental Therapeutics, 1988, 246 1: 170-176.
[2] DAVID BALDWIN. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis.[J]. BMJ : British Medical Journal, 2011: d1199. DOI: 10.1136/bmj.d1199
[3] BJOERN MOOSMANN Volker A Philippe Bisel. Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics[J]. Drug Testing and Analysis, 2014, 6 7-8: 757-763. DOI: 10.1002/dta.1628 |
|
|